SCHEDULE: Atlas Venture Maintains Significant Stake in Dyne Therapeutics
Beneficial Ownership Report (Amendment)
Atlas Venture and its affiliated funds collectively report a 6.4% beneficial ownership in Dyne Therapeutics, Inc. as of September 30, 2025.
Summary
- Atlas Venture and its affiliated entities collectively beneficially own 9,130,465 shares of Dyne Therapeutics, Inc. common stock.
- This aggregate ownership represents 6.4% of Dyne Therapeutics' outstanding common stock.
- The ownership is distributed across several Atlas Venture funds: Fund XI Reporting Persons (4.0%), Opportunity Fund Reporting Persons (1.0%), and Opportunity Fund II Reporting Persons (1.4%).
- The percentages are calculated based on 142,824,687 outstanding shares as of October 31, 2025, as reported in Dyne Therapeutics' Form 10-Q filed on November 5, 2025.
- This filing is an Amendment No. 5 to a Schedule 13G, indicating a previous reporting of beneficial ownership.
Sentiment
Score: 7
Explanation: The filing indicates a continued significant institutional stake by a prominent venture capital firm, which generally reflects confidence in the company's long-term prospects. While it is an ownership disclosure rather than a performance report, the sustained investment is a positive signal.
Positives
- Continued significant institutional investment by Atlas Venture, a prominent venture capital firm, signals confidence in Dyne Therapeutics' long-term prospects.
- The collective 6.4% stake provides a substantial and stable institutional shareholder base for the company.
Risks
- The Reporting Persons, while under common control, explicitly disclaim group membership for Section 13 purposes, which could imply potential for divergent interests among the various Atlas Venture entities despite their affiliation.
Industry Context
Institutional investors like Atlas Venture often take significant stakes in early-stage or growth-oriented biotechnology companies such as Dyne Therapeutics, providing crucial capital and strategic support. Their continued presence as a major shareholder can be viewed as a positive signal within the biotech investment community, suggesting ongoing belief in the company's potential.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Group Disclosure | The various Atlas Venture entities, while under common control, explicitly disclaim being a 'group' for Section 13 purposes, which impacts how their collective influence and reporting obligations are viewed. | 2025-09-30 | This disclaimer clarifies that while the entities are related, they do not formally acknowledge acting in concert as a single group, which could affect perceptions of coordinated shareholder action or control. |
Stakeholder Impact
- Shareholders: The continued significant ownership by Atlas Venture provides a stable institutional shareholder base, potentially signaling long-term commitment and confidence in Dyne Therapeutics' strategic direction and value creation.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of the event which required the filing of this statement, reflecting the beneficial ownership. |
| 2025-10-31 | Date as of which Dyne Therapeutics' outstanding common stock (142,824,687 shares) was reported in its Form 10-Q. |
| 2025-11-05 | Date Dyne Therapeutics' Form 10-Q was filed with the SEC, reporting outstanding shares. |
| 2025-11-13 | Date of filing for this Schedule 13G Amendment No. 5. |
Recommendation
holdThis Schedule 13G filing primarily discloses the beneficial ownership of Dyne Therapeutics by Atlas Venture and its affiliated funds. It indicates a continued significant institutional stake (6.4%) by a prominent venture capital firm. While this sustained investment is a positive signal of confidence, the filing itself does not contain new operational or financial performance data to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate for investors who already have a position, awaiting further fundamental updates from the company. For new investors, this filing confirms strong institutional backing but does not provide a direct catalyst for immediate action.
Keywords
Dyne Therapeutics, Atlas Venture, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Venture Capital, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.